In a composition in which L-ergothioneine (EGT) and N,N-dimethyl-L-2-thiohistidine (DTH), it makes possible to suppress coloring of the composition. A composition comprising EGT and DTH is prepared in which the content of DTH is reduced.

Composition for use in the prevention and/or in the treatment of cardiotoxicity induced by at least one chemotherapeutic agent in a subject undergoing chemotherapy, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid. Said chemotherapeutic agent may be selected in the group consisting of anthracyclines, HER2/ErbB2 inhibitors, tyrosine-kinase inhibitors, vascular endothelial growth factor inhibitors, immune checkpoint inhibitors.

Composition for use in the prevention and/or in the treatment of cardiotoxicity induced by at least one chemotherapeutic agent in a subject undergoing chemotherapy, the composition comprising an active agent, said active agent containing the amino acids leucine, isoleucine, valine, threonine, lysine and citric acid, succinic acid, malic acid. Said chemotherapeutic agent may be selected in the group consisting of anthracyclines, HER2/ErbB2 inhibitors, tyrosine-kinase inhibitors, vascular endothelial growth factor inhibitors, immune checkpoint inhibitors.

Prevention and treatment of immune deficiency and inflammation using cyclic histidyl-proline plus zinc (Cyclo-Z).

Prevention and treatment of immune deficiency and inflammation using cyclic histidyl-proline plus zinc (Cyclo-Z).

A method of treating diseases with the compound of Formula I is disclosed. The compound exhibits therapeutic effect to the treatment of various diseases including neurodegenerative diseases, muscular dystrophy, and cardiovascular diseases.

A method of treating diseases with the compound of Formula I is disclosed. The compound exhibits therapeutic effect to the treatment of various diseases including neurodegenerative diseases, muscular dystrophy, and cardiovascular diseases.

Provided is a liquid pharmaceutical composition having increased stability, and more particularly, a stable liquid pharmaceutical composition including a protein.

Provided is a liquid pharmaceutical composition having increased stability, and more particularly, a stable liquid pharmaceutical composition including a protein.

The present disclosure provides lyophilates comprising (S)-isopropyl 2-((S)-2-acetamido-3-(1H-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate: and pharmaceutical compositions, pharmaceutical formulations, and uses thereof.

##STR00001##